Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Blopress Keeps Top Place 5 Years in a Row
July 6, 2009
- New GL on COPD to Recommend β2 Stimulant + Inhaled Steroid Combinations
July 6, 2009
- FY2008 Sales of Ethical Drugs Up 2.9% to ¥8,368.6 Bil.: IMS Japan
July 6, 2009
- JSMI Introduces New Voluntary GL for Ad of OTC Drugs
July 6, 2009
- BUSINESS NEWS IN BRIEF
July 6, 2009
- Tamiflu Is Not Ineffective against Resistant Viruses
June 29, 2009
- BUSINESS NEWS IN BRIEF
June 29, 2009
- Pandemic of New-Type Flu Infections Unavoidable in Japan in Oct-Nov: Prof. Oshitani
June 29, 2009
- TOPICS 2 articles
June 29, 2009
- Memantine Dosage Titration Necessary in Patients with Renal Disorders
June 29, 2009
- Zithromac Leaps to Top Place in April: Rep Track Survey
June 29, 2009
- Expert Committee Recommends HbA1C for Diagnosis of Diabetes
June 29, 2009
- Distribution Business Reform in FY2008 Was Failure: Mr Matsutani
June 29, 2009
- R&D NEWS IN BRIEF
June 29, 2009
- Injectable Risperdal to Change Treatment of Schizophrenia: Janssen
June 29, 2009
- Japan Participates in Multinational PIII Study of JAK-3 Inhibitor: Pfizer
June 29, 2009
- Eli Lilly Japan to Increase Sales of Anticancer Drugs to 30% of Total Sales
June 29, 2009
- Top Quark to Create New CRO to Undertake Asian Trials
June 29, 2009
- Glufast, Urief to Drive Kissei's Growth: Dr Ajisawa
June 29, 2009
- Asahi Kasei Medical: Planova BioEX
June 29, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…